[1]闫 磊,徐 振,许莺歌,等.药物与支架植入术治疗特发性颅内高压伴静脉窦狭窄的疗效分析[J].介入放射学杂志,2025,34(08):816-821.[doi:10.3969/j.issn.1008-794X.2025.08.003 ]
　YAN Lei,XU Zhen,XU Yingge,et al.Medication versus stenting for the treatment of idiopathic intracranial hypertension with venous sinus stenosis:analysis of clinical efficacy[J].J Intervent Med,2025,34(08):816-821.[doi:10.3969/j.issn.1008-794X.2025.08.003 ]
点击复制

药物与支架植入术治疗特发性颅内高压伴静脉窦狭窄的疗效分析 ()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
34
期数:
2025年08
页码:
816-821
栏目:
神经介入
出版日期:
2025-08-25

文章信息/Info

Title:
Medication versus stenting for the treatment of idiopathic intracranial hypertension with venous sinus stenosis:analysis of clinical efficacy
文章编号:
1008-794X(2025)-008-0816-06
作者:
闫 磊;  徐 振;  许莺歌;  包雯颍;  张 松;  朱 明;  吴垠垠;  水少锋
450052 河南郑州 郑州大学第一附属医院放射介入科
Author(s):
YAN Lei; XU Zhen; XU Yingge; BAO Wenying; ZHANG Song; ZHU Ming; WU Yinyin; SHUI Shaofeng.
Department of Interventional Radiology,First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan Province 450052,China
关键词:
特发性颅内高压;  静脉窦狭窄;  支架植入术;  药物治疗
分类号:
R543.6
DOI:
10.3969/j.issn.1008-794X.2025.08.003
文献标志码:
A
摘要:
目的 对比药物与支架植入术治疗特发性颅内高压伴静脉窦狭窄患者的疗效。方法 回顾性分析2020年1月至2023年6月郑州大学第一附属医院收治的74例特发性颅内高压伴静脉窦狭窄患者的临床资料。采用单纯药物治疗(药物组)35例,支架植入术治疗(支架组)39例。治疗前后均行腰椎穿刺术评估颅内压的改善情况,并行眼底检查评估视乳头水肿的改善情况。比较两组患者住院期间视乳头水肿Frisén分级中位数和腰椎穿刺开口压力平均值的变化。比较出院时、出院后6个月和12个月随访时临床症状的改善情况。观察随访期间两组患者的并发症发生情况。结果 两组患者除支架组发病至治疗的时间较长(2 vs 1个月, P =0.021),其余基线资料差异均无统计学意义(均 P >0.05)。两组患者治疗后均有不同程度的好转(均 P >0.05)。但出院时支架组患者乳头水肿Frisén分级中位数更低(1 vs 2, P =0.011); 腰椎穿刺开口压力(lumbar punctureopening pressure,LPOP)平均值更低(205.26 vs 248.14 mmH2O, P =0.002)。出院时(74.4% vs 45.7%, P =0.017)、出院后6个月(84.6% vs 48.6%, P =0.001)、12个月(87.2% vs 57.1%, P =0.004)随访时支架组患者无症状和症状改善的患者比例更高。支架组并发症发生率略高,但差异无统计学意义(10.3% vs 8.6%, P =1.000)。结论 与药物治疗相比,支架植入术治疗特发性颅内高压伴静脉窦狭窄患者能更快速有效地缓解视乳头水肿、腰椎穿刺开口压力及其相应症状和体征,改善患者预后且安全性相当。

参考文献/References:

[1] Asif H,Craven CL,Siddiqui AH,et al.Idiopathic intracranial hypertension:120-day clinical,radiological,and manometric outcomes after stent insertion into the dural venous sinus[J].J Neurosurg,2018,129:723-731.
[2]Wang M,Bhatti MT,Danesh-Meyer HV.Idiopathic intracranial hypertension:Pathophysiology,diagnosis and management[J].J Clin Neurosci,2022,95:172-179.
[3]李熙星,崔卫娜.特发性颅内高压的临床表现与诊治策略[J].中华耳鼻咽喉头颈外科杂志,2023,58:384-388.
[4]McGovern RA,Kelly KM,Chan AK,et al.Should ventriculoatrial shunting be the procedure of choice for normal-pressure hydrocephalus?[J].J Neurosurg,2014,120:1458-1464.
[5]Mukherjee N,Bhatti MT.Update on the surgical management of idiopathic intracranial hypertension[J].Curr Neurol Neurosci Rep,2014,14:438.
[6]Fargen KM,Coffman S,Torosian T,et al.“Idiopathic” intracranial hypertension:an update from neurointerventional research for clinicians[J].Cephalalgia,2023,43:3331024231161323.
[7]Durst CR,Ornan DA,Reardon MA,et al.Prevalence of dural venous sinus stenosis and hypoplasia in a generalized population[J].J Neurointerv Surg,2016,8:1173-1177.
[8]白卫星,贺迎坤,康晓雨,等.股静脉入路脑静脉窦内支架成形术治疗特发性颅内高压伴静脉窦狭窄13例[J].介入放射学杂志,2020,29:650-653.
[9]康晓雨,白卫星,许 斌,等.静脉窦内支架成形术治疗特发性颅高压合并颅内静脉窦狭窄的单中心随访研究[J].中华神经外科杂志,2023,39:466-470.
[10]Raynald,Yang H,Tong X,et al.Stenting versus medical treatment for idiopathic intracranial hypertension:a matched-control study[J].J Neurointerv Surg,2023,15:1021-1026.
[11]Rook BS,Phillips PH.Pediatric pseudotumor cerebri[J].Curr Opin Ophthalmol,2016,27:416-419.
[12]Deliz JR,Tanner CM,Gonzalez-Latapi P.Epidemiology of Parkinson's Disease:an update[J].Curr Neurol Neurosci Rep,2024,24:163-179.
[13]ten Hove MW,Friedman DI,Patel AD,et al.Safety and tolerability of acetazolamide in the idiopathic intracranial hypertension treatment trial[J].J Neuroophthalmol,2016,36:13-19.
[14]NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee,Wall M,McDermott MP,et al.Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss:the idiopathic intracranial hypertension treatment trial[J].JAMA,2014,311:1641-1651.
[15]Cheng H,Jin H,Hu Y,et al.Long-term efficacy of venous sinus stenting in the treatment of idiopathic intracranial hypertension[J].CNS Neurosci Ther,2024,30:e14356.
[16]Raynald,Huo X,Yang H,et al.Characteristics and outcomes of the idiopathic intracranial hypertension treatment in intrinsic and extrinsic stenosis:a single-center experience in China[J].Neurol Ther,2021,10:1029-1044.
[17]Cappuzzo JM,Hess RM,Morrison JF,et al.Transverse venous stenting for the treatment of idiopathic intracranial hypertension,or pseudotumor cerebri[J].Neurosurg Focus,2018,45:E11.
[18]Nicholson P,Brinjikji W,Radovanovic I,et al.Venous sinus stenting for idiopathic intracranial hypertension:a systematic review and meta-analysis[J].J Neurointerv Surg,2019,11:380-385.
[19]Saber H,Lewis W,Sadeghi M,et al.Stent survival and stent-adjacent stenosis rates following venous sinus stenting for idiopathic intracranial hypertension:a systematic review and meta-analysis[J].Interv Neurol,2018,7:490-500.
(收稿日期:2024-10-11)
(本文编辑:茹 实)

相似文献/References:

[1]陈怀瑞,白如林,吴小军,等.狭窄静脉窦支架扩张治疗假脑瘤综合征[J].介入放射学杂志,2011,(01):10.
　CHEN Huai-rui,BAI Ru-lin,WU Xiao-jun,et al.Venous sinus stenting for pseudotumour cerebri with venous sinus stenosis[J].J Intervent Med,2011,(08):10.
[2]徐 振,包雯颍,许莺歌,等.支架植入术治疗特发性颅内高压伴不同类型静脉窦狭窄效果比较[J].介入放射学杂志,2025,34(07):697.[doi:10.3969/j.issn.1008-794X.2025.07.003]
　XU Zhen,BAO Wenying,XU Yingge,et al.Stenting for the treatment of idiopathic intracranial hypertension complicated by different types of venous sinus stenosis:a comparative study[J].J Intervent Med,2025,34(08):697.[doi:10.3969/j.issn.1008-794X.2025.07.003]

备注/Memo

备注/Memo:
通信作者: 水少锋 E-mail:shuishaofeng@126.com
更新日期/Last Update: 2025-08-25